CD274 and cancer: To further support our findings, we modified the above setup and simulated additional suppression by PD-L1+ cancer cells in the tumor microenvironment by adding 10 μg/mL of soluble (s) cPD-L1 to the activated cPBMCs (Figure 3G and Figure S3C).